All In Biotech

Drug Trial Radar · NCT06547216

Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

A Phase 2 Open-label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AOC 1020 Administered Intravenously to Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

Last checked: Nov 20, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Jul 25, 2024

Primary completion

Apr 2030

Study completion Jun 2030

Sponsor

Lead sponsor
Avidity Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Aug 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years, up to 72 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2 Open-label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)

Conditions

  • FSHD
  • FSHD1
  • FSHD2
  • FMD
  • FMD2
  • Fascioscapulohumeral Muscular Dystrophy
  • Fascioscapulohumeral Muscular Dystrophy Type 1
  • Fascioscapulohumeral Muscular Dystrophy Type 2
  • Dystrophies, Facioscapulohumeral Muscular
  • Dystrophy, Facioscapulohumeral Muscular
  • Facioscapulohumeral Muscular Dystrophy 1
  • Facioscapulohumeral Muscular Dystrophy 2
  • Facio-Scapulo-Humeral Dystrophy
  • Atrophy, Facioscapulohumeral
  • Atrophies, Facioscapulohumeral
  • Facioscapulohumeral Atrophy
  • Muscular Dystrophies
  • Muscular Dystrophy, Facioscapulohumeral
  • FSH Muscular Dystrophy
  • Landouzy Dejerine Dystrophy
  • Landouzy-Dejerine Muscular Dystrophy
  • Dystrophies, Landouzy-Dejerine
  • Dystrophy, Landouzy-Dejerine
  • Landouzy-Dejerine Syndrome
  • Muscular Dystrophy, Landouzy Dejerine
  • Progressive Muscular Dystrophy
  • FSH

Interventions

  • AOC 1020Drug

    AOC 1020 will be administered via intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse eventsTime frame: Through study completion, up to Day 729

Locations

17 sites in 3 countries. Site status is shown where the registry gives one.

  • University of California Los Angeles

    Los Angeles, California

  • Stanford University

    Palo Alto, California

  • University of California San Diego

    San Diego, California

  • University of Colorado

    Denver, Colorado

  • University of Florida

    Gainesville, Florida

  • Rare Disease Research

    Atlanta, Georgia

  • Kansas University Medical Center

    Kansas City, Kansas

  • University of Rochester Medical Center

    Rochester, New York

  • Duke University

    Durham, North Carolina

  • Ohio State University

    Columbus, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • University of Texas Southwestern

    Dallas, Texas

  • Virginia Commonwealth University

    Richmond, Virginia

  • University of Washington

    Seattle, Washington

  • University of Ottawa

    Ottawa, Ontario, Canada

  • University College London

    London, United Kingdom

  • University of Sheffield

    Sheffield, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.